金复康口服液联合胸腺肽α1对气阴两虚型非小细胞肺癌患者的临床疗效  

Clinical effects of Jinfukang Oral Liquid combined with thymosinα1 on patients with non-small cell lung cancer due to Dual Deficiency of Qi and Yin

作　　者：吴冠锦 黄默菲 亓奥 田雪琪 王德才 焦丽静 许玲[1,2] WU Guan-jin;HUANG Mo-fei;QI Ao;TIAN Xue-qi;WANG De-cai;JIAO Li-jing;XU Ling(Department of Oncology I,Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200437,China;Institute of Traditional Chinese Medicine Oncology,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;Institute of Integrated Traditional Chinese and Western Medicine on Tumor Transition,Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200437,China)

机构地区：[1]上海中医药大学附属岳阳中西医结合医院肿瘤一科,上海200437 [2]上海中医药大学附属龙华医院中医肿瘤研究所,上海200032 [3]上海中医药大学附属岳阳中西医结合医院中西医结合肿瘤转化研究所,上海200437

出　　处：《中成药》2025年第3期790-795,共6页Chinese Traditional Patent Medicine

基　　金：国家科技部“国家重点研发计划”中医药现代化专项(2023YFC3503302);国家自然科学基金项目(82274595);上海市科委“科技创新行动计划”医学创新研究专项(22Y31920400);上海市高峰高原高水平建设项目(KY110.01.400);上海市中医肿瘤临床医学研究中心(21MC1930500)。

摘　　要：目的探讨金复康口服液联合胸腺肽α1对气阴两虚型非小细胞肺癌患者的临床疗效。方法75例患者随机分为胸腺肽α1组(15例)、金复康口服液组(30例)、联合组(30例),疗程4周。检测中医临床证候疗效、免疫指标(CD3^(+)T、Th、CTL、总NK、CD56^(dim)CD16^(+)NK、NKT、Treg、MDSC)、杀伤力/抑制力比值(CTL/Treg、总NK/Treg、NKT/Treg、CTL/MDSC、总NK/MDSC、NKT/MDSC)、FACT-L评分变化。结果金复康口服液组、联合组总有效率高于胸腺肽α1组(P<0.05)。治疗后,金复康口服液组、联合组NKT升高(P<0.05),MDSC降低(P<0.05),比胸腺肽α1组更明显(P<0.05),金复康口服液组NKT更高(P<0.05);金复康口服液组、联合组杀伤力/抑制力比值升高(P<0.05),其中NKT/Treg、CTL/MDSC、总NK/MDSC、NKT/MDSC高于胸腺肽α1组(P<0.05),金复康口服液组CTL/MDSC、NKT/MDSC更高(P<0.05);金复康口服液组(除生理状况、社会家庭状况外)、联合组(除社会家庭状况外)FACT-L评分升高(P<0.05)。结论金复康口服液单用或联合胸腺肽α1可提高气阴两虚型非小细胞肺癌患者外周血免疫监视,抑制免疫逃逸,恢复肿瘤免疫反应平衡状态,改善中医证候和生活质量。AIM To explore the clinical effects of Jinfukang Oral Liquid combined with thymosinα1 on patients with non-small cell lung cancer due to Dual Deficiency of Qi and Yin.METHODS Seventy-five patients were randomly assigned into thymosinα1 group(15 cases)for 4-week administration,Jinfukang Oral Liquid group(30 cases)for 4-week administration,and combination group(30 cases)for 4-week administration.The changes in TCM clinical syndrome effects,immunity indices(CD3^(+)T,Th,CTL,total NK,CD56^(dim)CD16^(+)NK,NKT,Treg,MDSC),lethality/inhibition ratios(CTL/Treg,total NK/Treg,NKT/Treg,CTL/MDSC,total NK/MDSC,NKT/MDSC)and FACT-L scores were detected.RESULTS The Jinfukang Oral Liquid group and combination group demonstrated higher total effective rates than the thymosinα1 group(P<0.05).After the treatment,the Jinfukang Oral Liquid group and combination group displayed increased NKT(P<0.05)and decreased MDSC(P<0.05),which were more obvious than those in the thymosinα1 group(P<0.05),and higher NKT was observable in the Jinfukang Oral Liquid group(P<0.05);the Jinfukang Oral Liquid group and combination group displayed increased lethality/inhibition ratios(P<0.05),among which NKT/Treg,CTL/MDSC,total NK/MDSC,NKT/MDSC were higher than those in the thymosinα1 group(P<0.05),and higher CTL/MDSC,NKT/MDSC were observable in the Jinfukang Oral Liquid group(P<0.05);the Jinfukang Oral Liquid group(except for physiological status,society and family status)and combination group(except for society and family status)displayed increased FACT-L scores(P<0.05).CONCLUSION For the patients with non-small cell lung cancer due to Dual Deficiency of Qi and Yin,Jinfukang Oral Liquid single use or combined with thymosinα1 can enhance peripheral blood immune surveillance,inhibit immune escape,restore the balanced state of tumor immune responses,and improve TCM syndromes and life quality.

关 键 词：金复康口服液 胸腺肽Α1 非小细胞肺癌 气阴两虚 免疫调节 生活质量 

分 类 号：R287[医药卫生—中药学]